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Abstract
Background: Hypertension and diabetes prevalence is high in Africans. Data from HIV infected populations are
limited, especially from Malawi. Integrating care for chronic non-communicable co-morbidities in well-established
HIV services may provide benefit for patients by preventing multiple hospital visits but will increase the burden of
care for busy HIV clinics.
Methods: Cross-sectional study of adults (≥18 years) at an urban and a rural HIV clinic in Zomba district, Malawi,
during 2014. Hypertension and diabetes were diagnosed according to stringent criteria. Proteinuria, non-fasting
lipids and cardio/cerebro-vascular disease (CVD) risk scores (Framingham and World Health Organization/
International Society for Hypertension) were determined. The association of patient characteristics with diagnoses of
hypertension and diabetes was studied using multivariable analyses. We explored the additional burden of care for
integrated drug treatment of hypertension and diabetes in HIV clinics. We defined that burden as patients with
diabetes and/or stage II and III hypertension, but not with stage I hypertension unless they had proteinuria,
previous stroke or high Framingham CVD risk.
Results: Nine hundred fifty-two patients were enrolled, 71.7% female, median age 43.0 years, 95.9% on antiretroviral
therapy (ART), median duration 47.7 months. Rural and urban patients’ characteristics differed substantially.
Hypertension prevalence was 23.7% (95%-confidence interval 21.1–26.6; rural 21.0% vs. urban 26.5%; p = 0.047), of
whom 59.9% had stage I (mild) hypertension. Diabetes prevalence was 4.1% (95%-confidence interval 3.0–5.6)
without significant difference between rural and urban settings. Prevalence of proteinuria, elevated total/high-
density lipoprotein-cholesterol ratio and high CVD risk score was low. Hypertension diagnosis was associated with
increasing age, higher body mass index, presence of proteinuria, being on regimen zidovudine/lamivudine/
nevirapine and inversely with World Health Organization clinical stage at ART initiation. Diabetes diagnosis was
associated with higher age and being on non-standard first-line or second-line ART regimens.
Conclusion: Among patients in HIV care 26.6% had hypertension and/or diabetes. Close to two-thirds of
hypertension diagnoses was stage I and of those few had an indication for antihypertensive pharmacotherapy.
According to our criteria, 13.0% of HIV patients in care required drug treatment for hypertension and/or diabetes.
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Background
In a national survey from 2009, high prevalence of
hypertension (33%) and diabetes mellitus (6%) was ob-
served in the Malawi general population [1]. Both condi-
tions are likely to become even more common due to
population transition effects related to urbanization, life
style changes associated with increasing wealth, as well
as increasing age of the population [2]. The World
Health Organization (WHO) predicts that the burden of
hypertension in sub-Saharan Africa will double between
2000 and 2025 [3]. The main complications of hyperten-
sion and diabetes mellitus, such as heart failure, stroke,
myocardial infarction and renal failure have not been
well studied at population level in Malawi, but are com-
mon reasons for admissions to medical departments [4].
It has therefore been widely argued that hypertension
and diabetes mellitus need to get more public health pri-
ority [5]. Both conditions are also common among HIV
infected patients. One small study showed a hyperten-
sion prevalence of 46% among Blantyre anti-retroviral
therapy (ART) patients [6] but further information from
Malawi has not been published. HIV and antiretroviral
drugs are believed to increase the incidence of diabetes
mellitus according to western studies [7], which is com-
pounded by the increased life expectancy of persons liv-
ing with HIV and a longer mean exposure to ART. The
adult Malawian population on ART is very large
(>550,000 persons) and will continue to grow as eligibil-
ity for ART extends.
Because persons living with HIV are under regular fol-
low up in the health care system, they can benefit from
integrated screening and treatment of hypertension and
diabetes mellitus at HIV clinics. When planning integra-
tion of hypertension and diabetes management into HIV
services, the increased burden for busy HIV clinics has
to be considered. How large that burden is, will be de-
termined by the prevalence of hypertension and diabetes
as well as by the percentage of patients that need
pharmacotherapy which requires more frequent and lon-
ger clinic visits. For persons with mild hypertension,
who do not have cardio/cerebro-vascular disease (CVD)
or target organ damage and have low CVD risk, antihy-
pertensive drug treatment may not be indicated.
We conducted a study in two HIV clinics in Zomba
district, Malawi to estimate the prevalence of hyperten-
sion, diabetes mellitus and CVD risk factors among
adult Malawians in HIV care and to explore the burden
of patients in need of integrated pharmacotherapy.
Methods
Study setting
A cross-sectional study was carried out at the HIV
clinics of Zomba Central Hospital (urban setting, around
7000 patients) and Pirimiti Rural Hospital (rural setting,
around 4000 patients). Both clinics are located in Zomba
district, southern Malawi, where HIV prevalence is
around 14.5% in the 15–49 year age group [8]. After the
study we started implementation of integrated HIV-
hypertension-diabetes treatment at one of the clinics
and will report this experience elsewhere.
Participants and data collection
Consecutive patients aged ≥18 years accessing HIV care
were included in the study. Participants were inter-
viewed by trained research assistants using a structured
questionnaire in the local language or English, according
to patients’ preference. Household size was defined as
number of people aged ≥18 years living in the partici-
pant’s household. Self-reported physical activity was cat-
egorized as vigorously-, moderately- and in-active, based
on the STEPS questionnaire, developed by WHO for
non-communicable disease surveillance [1]. In this
methodology, inadequate fruit and vegetable consump-
tion is defined as eating less than 5 servings of fruit and/
or vegetables per day. Because virtually all (>99.5%) par-
ticipants had an inadequate diet using these criteria, we
used the mean number of vegetable servings per day as
a variable in our analyses. HIV-related information was
extracted from standard clinic registers and master
cards. Physical measurements were performed by study
nurses. Participants were asked to rest on a chair for
15 min before three digital blood pressure measure-
ments (Rossmax® AW 150f, Jena, Germany) were taken,
three minutes apart. Non-fasting capillary blood samples
were collected for all biochemical tests. Blood glucose
was measured with the point-of-care SD CHECK™
GOLD Blood Glucose Meter (SD Biosensor, Inc.,
GyeongGi-do, Republic of Korea). A follow up fasting
blood glucose was collected if the blood glucose level
was >200 mg/dl. Blood lipid levels were determined
using the point-of-care CardioChek® PA (Polymer Tech-
nology Systems, Inc., Indianapolis, USA) in a sub-sample
of the first 277 enrolled patients at each clinic. Urine
protein was measured with SD UroColorTM10 urine dip-
sticks that provide a semi-quantitative result (Standard
Diagnostics, Inc., Kyonggi-do, Republic of Korea); nega-
tive and trace results were considered as normal.
Clinical definitions
Hypertension was defined as a systolic blood pressure
(SBP) of ≥140 mmHg and/or diastolic blood pressure
(DBP) ≥90 mmHg of the mean of the first 3 BP measure-
ments and confirmed at two follow-up visits within two
weeks. Hypertension was categorized as follows: stage I
(mild) hypertension SBP 140–159 mmHg and/or DBP
90–99 mmHg, stage II (moderate) SBP 160–179 mmHg
and/or DBP 100–109 mmHg and stage III (severe) SBP
≥180 mmHg and/or DBP ≥110 mmHg. Patients on anti-
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hypertensive treatment were regarded as having hyperten-
sion irrespective of blood pressure readings and were not
staged. Body mass index (BMI) was categorized according
to WHO thresholds [9]. Central obesity was defined as
waist-hip ratio (waist circumference/hip circumference) of
≥0.94 for men and ≥0.80 for women [10]. Diabetes melli-
tus was diagnosed if an elevated blood glucose level was
recorded on two separate occasions: >126 mg/dL if the
patient was fasting and >200 mg/dL if not. Participants
already on antidiabetic drugs were regarded as diabetics ir-
respective of their blood glucose level. Total cholesterol
(TC) was elevated if >5.2 mmol/L. High-density lipopro-
tein cholesterol (HDL-c) was decreased if <1.1 mmol/L.
Triglyceride (TG) upper level of normal was 2.9 mmol/L.
The TC/HDL-c ratio was used as an indicator of increased
CVD risk and considered elevated if >5. Framingham risk
score (FRS) and WHO/International Society for Hyper-
tension (WHO/ISH) risk scores were calculated for all pa-
tients where possible [11, 12] We used the mean of the 3
blood pressure measurements of the first visit in both risk
scores. FRS includes sex, age (≥20 years), current smoking
status, total cholesterol, HDL-cholesterol, anti-
hypertensive drug use and systolic blood pressure. Two
WHO/ISH risk scores are based on prediction charts for
the African region [12]. One includes sex, age (≥40 years),
smoking status, systolic BP and diabetes status, the second
also includes TC. Since the WHO/ISH risk prediction
charts exclude those aged <40, these scores could not be
calculated for 573 patients.
Statistical analysis
The sample size was based on the expected prevalence
of hypertension from a previous study in Malawi (ref 6),
a desired precision of 5%, a 95% confidence interval and
adding 25% for non-response; 471 participants were thus
required per clinic (i.e. 942 in total). Data were entered
in an Access database, cleaned, coded and merged ready
for analysis using Stata 13 (Statacorp, College Station
Texas, USA). We described patients’ demographic and
clinical characteristics and cardiovascular risk factors
separately for urban and rural clinics. Point-prevalence
of hypertension, diabetes, hyperlipidemia, proteinuria
and high CVD risk scores is reported with 95%-confi-
dence intervals (95%-CI). Univariate and multivariable
logistic regression analyses were performed to determine
independent risk factors for hypertension and diabetes
mellitus. Age, gender, study site and educational status
were kept in the model as a priori confounder regardless
of degree of association in univariate analysis. Protein-
uria was omitted from the diabetes final model due to
insufficient numbers. The significance of the association
between patients’ characteristics and outcomes in the
models was assessed using a likelihood ratio test. P-
value for trend is reported as appropriate. To estimate
the burden of drug treatment for hypertension and dia-
betes in the HIV population in care, we included all pa-
tients with diabetes diagnosis, and those with stage II
and III hypertension. We added patients with stage I
hypertension who had coexisting proteinuria, self-
reported previous stroke, and/or a high FRS. The total
number with high FRS was determined by extrapolation
using the percentage found among patients with stage I
hypertension in whom the score could be determined,
i.e. those with lipid measurements. At each clinic, we
compared routinely collected patients characteristics of
the overall clinic population aged ≥18 years to those of
the study population, to assess if the study sample was
representative of all HIV patients in care.
Results
Demographic, life-style and clinical characteristics
Between July and October 2014, we enrolled 952 pa-
tients, 480 in the urban and 472 in the rural clinic. The
median age was 43 years and 683 (71.7%) were female.
Urban patients had higher education levels, were more
frequently employed, less physically active, ate more veg-
etables and fruits, used less smokeless tobacco, were
more often on ART, had a longer duration of HIV infec-
tion and duration on ART, less advanced clinical HIV
disease at the start of ART, were less commonly on the
standardized first-line ART regimen and had a higher
BMI than rural patients. Overall prevalence of smoking
and alcohol usage was low (Table 1). When comparing
the study populations with the overall adult patient pop-
ulations at each clinic, we found that the study popula-
tions were significantly older, longer on ART, and less
often on the standardized first-line regimen, while only
in the urban clinic the percentage of females was higher
than in the overall patient population (data not shown).
Hypertension and diabetes prevalence and risk factors
Hypertension was diagnosed in 226 patients, resulting
in an overall prevalence of 23.7% (95%-CI 21.1–26.6),
which included 29 patients (12.8%) already on pharma-
cotherapy and 166 (73.5%) newly diagnosed cases. Of
patients with untreated hypertension (n = 197; 87.2%),
118 (59.9%) had stage I hypertension, 61 (31.0%) stage
II and 18 (9.1%) stage III. Hypertension was more com-
mon among urban patients (Table 2). Variables that
were independently associated with a diagnosis of
hypertension were increasing age, obesity, current ART
regimen zidovudine/lamivudine/nevirapine and pres-
ence of proteinuria, while an inverse independent asso-
ciation was observed with WHO clinical stage at ART
initiation (Table 3). We diagnosed 39 patients with dia-
betes mellitus, of whom 10 (25.6%) were already on
pharmacotherapy. The overall prevalence of diabetes
mellitus was 4.1% (95%–CI 3.0–5.6), similar in urban
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Table 1 Characteristics of patients in HIV care in a rural and an urban clinic, Zomba District, Malawi
Characteristics Total Rural Urban P-value
n (%) n (%) n (%)
Number of patients 952 472 (49.6) 480 (50.4)
Gender
Female 683 (71.7) 334 (70.8) 349 (72.7) 0.505
Male 269 (28.3) 138 (29.2) 131 (27.3
Age in years (N = 952) 0.250
18–34 210 (22.1) 111 (23.5) 99 (20.6)
35–44 361 (37.9) 182 (38.6) 179 (37.3)
45–54 238 (25.0) 105 (22.3) 133 (27.7)
≥ 55 143 (15.0) 74 (15.7) 69 (14.4)
Mean age (SD) in years 43.0 (10.2) 42.7 (10.6) 43.2 (9.8) 0.471
Educational status
None 204 (21.5) 143 (30.3) 61 (12.7) <0.001
Standard 1–8 576 (60.6) 283 (60.0) 293 (61.2)
Secondary & above 171 (18.0) 46 (9.8) 125 (26.1)
Household size mean (SD) 2.58 (1.26) 2.55 (1.17) 2.62 (1.35) 0.401
Employment status
Employed 112 (11.8) 17 (3.6) 95 (19.8) <0.001
Unemployed 255 (26.8) 38 (8.1) 217 (45.2)
Self Employed 585 (61.5) 417 (88.4) 168 (35.0)
Physical activity
Vigorously active 854 (89.7) 458 (97.0) 396 (82.5) <0.001
Moderately active 90 (9.5) 11 (2.3) 79 (16.5)
Inactive individuals 8 (0.8) 3 (0.6) 5 (1.0)
Dietary history
Mean days of fruit consumption/wk (SD) 2.63 (2.06) 2.31 (1.87) 2.98 (2.20) <0.001
Mean servings of fruit/day (SD) 1.25 (0.76) 1.20 (0.74) 1.31 (0.79) 0.028
Mean days of vegetables consumption/wk (SD) 5.13 (1.95) 4.51 (1.88) 5.73 (1.83) <0.001
Mean servings of vegetables/day (SD) 1.81 (0.49) 1.77 (0.50) 1.85 (0.47) 0.006
Tobacco
Ever smoked tobacco 117 (12.3) 50 (10.6) 67 (14.0) 0.114
Current tobacco smokers 34 (3.6) 19 (4.3) 15 (3.1) 0.454
Daily tobacco smoker 25 (2.6) 15 (3.2) 10 (2.1) 0.291
Current smokeless tobacco users 21 (2.2) 15 (3.2) 6 (1.3) 0.041
Alcohol
Used alcohol in the past 30 days (current drinker) 61 (6.4) 33 (7.0) 28 (5.8) 0.466
Used alcohol in the past 12 months 97 (10.2) 56 (11.9) 41 (8.5) 0.090
Self-report of previous stroke
Yes 41 (4.3) 26 (5.5) 15 (3.1) 0.070
No 909 (95.7) 445 (94.5) 464 (96.9)
Self-report of previous myocardial infarction
Yes 211 (22.2) 113 (24.0) 98 (20.5) 0.190
No 739 (77.8) 358 (76.0) 381 (79.5)
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and rural patients (Table 2). A diagnosis of diabetes
mellitus was independently associated with current
ART regimen other than tenofovir/lamivudine/efavir-
enz and zidovudine/lamivudine/nevirapine, and with
increasing age (Table 3).
Proteinuria, dyslipidaemia and CVD risk scores
Proteinuria prevalence was 2.1% and significantly higher
in urban patients (Table 2). We screened the first 277
patients enrolled in each clinic for dyslipidaemia. Preva-
lence of elevated total cholesterol was 15.5%, decreased
HDL-cholesterol 15.9%, elevated triglycerides 28.7% and
elevated total cholesterol/HDL-cholesterol ratio 3.8%
(Table 2). There was no significant difference in preva-
lence of dyslipidaemias between rural and urban pa-
tients. We were unable to determine CVD risk scores in
many patients due to age restrictions and our limitation
of having lipids from 554 patients. We report the preva-
lence of a combined risk of >20% to experience a fatal or
non-fatal myocardial infarction or stroke in the next 10
years. This prevalence was low among those tested:
using the WHO/ISH score excluding total cholesterol (n
= 379), prevalence was 3.4% and with the same score in-
cluding total cholesterol (n = 187) was 2.1%; using the
FRS (n = 551) prevalence was 2.4% (Table 2).
Expected burden of integrated pharmacological
treatment
Of patients with stage I hypertension, 86.4% had a low
risk FRS in combination with absence of diabetes, pro-
teinuria, and previous stroke. As they would not have an
indication for drug treatment, overall 10.0% of the HIV
patients in care were in need of antihypertensive
pharmacotherapy. The total burden of pharmacological
Table 1 Characteristics of patients in HIV care in a rural and an urban clinic, Zomba District, Malawi (Continued)
ART Status
On ART 913 (95.9) 443 (93.9) 470 (97.9) 0.002
Pre-ART 39 (4.1) 29 (6.1) 10 (2.1)
Mean HIV infection duration (SD), months 55.4 (31.7) 49.7 (32.2) 61.0 (30.2) <0.001
Mean ART duration (SD), months 47.7 (29.3) 42.1 (29.0) 53.0 (28.7) <0.001
CD4 count at ART initiation, mean (SD) (n = 632) 217.5 (114.6) 216.9 (121.0) 218.1 (108.2) 0.898
WHO stage at ART initiation
WHO Stage 1 275 (30.1) 171 (38.6) 104 (22.1) <0.001
WHO Stage 2 306 (33.5) 139 (31.4) 167 (35.5)
WHO Stage 3 270 (29.5) 110 (24.8) 160 (34.0)
WHO Stage 4 63 (6.9) 23 (5.2) 40 (8.5)
Current ART Regimen
2Aa 107 (11.7) 33 (7.5) 74 (15.7) <0.001
5Ab 775 (84.9) 397 (89.6) 378 (80.4)
Other 31 (3.4) 13 (2.9) 18 (3.8)
Mean BMI (SD), kg/m2 21.9 (3.4) 21.3 (3.2) 22.6 (3.6) <0.001
BMI categories, n (%)
Under weight (<18.5 kg/m2) 102 (10.7) 65 (13.8) 37 (7.7) <0.001
Normal (18.5–25 kg/m2) 682 (71.6) 349 (73.9) 333 (69.4)
Over weight (>25–30 kg/m2) 132 (13.9) 45 (9.5) 87 (18.1)
Obesity (>30 kg/m2) 36 (3.8) 13 (2.8) 23 (4.8)
Waist to hip ratio, n (%)
High 249 (26.9) 122 (27.1) 127 (26.6) 0.867
Normal 678 (73.1) 328 (72.9) 350 (73.4)
Proteinuria
Normal (negative or trace) 928 (97.9) 470 (99.6) 458 (97.9) 0.001
1+ 13 (1.4) 2 (0.4) 11 (2.3)
2+ 7 (0.7) 0 7 (1.5)
SD standard deviation, BMI body mass index
a2A, generic single tablet formulation of zidovudine, lamivudine, nevirapine
b5A, generic single tablet formulation of tenofovir, lamivudine, efavirenz
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treatment for hypertension and/or diabetes among HIV
patients in care, with its associated longer and more fre-
quent clinic visits, was 13.0%. This included all patients
with diabetes diagnosis, stage II and III hypertension
and those with stage I hypertension and proteinuria, pre-
vious stroke, and/or high risk FRS.
Discussion
Among nearly 1000 adult Malawians in HIV care, the
vast majority on ART, we found that the prevalence of
hypertension was 23.7%. Hypertension was previously
undiagnosed in three quarters, significantly more com-
mon at the urban clinic (absolute difference 5.5%) and in
nearly two-thirds it was mild (stage I). Diabetes mellitus
was present in 4.8% of hypertensive patients. An earlier
study of urban ART patients from Malawi found a much
higher hypertension prevalence (46%), which may be ex-
plained by the less stringent blood pressure measure-
ment methodology than in our study and a small sample
size [6]. Several other studies from the region found
more comparable hypertension prevalence among ART
patients. In two urban studies from Tanzania, prevalence
was 28.7% [13] and 26.2% [14] and in a large peri-urban
cohort in Uganda 27.9% [15]. In a referral hospital in
Cameroon 38% of ART patients had hypertension [16].
In a recent, large (n >25,000 adults; HIV prevalence
10%), population-based study in a rural and an urban
area in Malawi, overall hypertension prevalence was 13–
16% and diabetes prevalence 1.8–2.6%, and these rates
were slightly lower in HIV infected persons [17].
We found that increasing age was independently associ-
ated with hypertension, while there was a borderline associ-
ation with higher BMI. Ageing and obesity are well
established risk factors for hypertension [3] but our obser-
vation that being on zidovudine-lamivudine-nevirapine was
associated with hypertension is surprising. To our know-
ledge, there is no literature linking either zidovudine or ne-
virapine to hypertension and this finding therefore needs
confirmation. Proteinuria was associated with hypertension,
but prevalence was low in our population, possibly related
to the fairly low mean age, low rates of moderate/severe
hypertension and diabetes and the fact that nearly all pa-
tients were on ART. The prevalence of diabetes in our
population (4.1%) was slightly lower than observed in the
general Malawi population (5.6%), with no significant differ-
ence between rural and urban patients. One quarter was
previously diagnosed and on medication. There was an ex-
pected association of diabetes with higher age. The only
other independent risk factor for diabetes was being on an
“other” ART regimen. This category included protease in-
hibitors and stavudine, drugs known to increase the risk of
diabetes [17, 18]. Studies among sub-Saharan African ART
patients showed fairly similar diabetes prevalences: 1.2%
raised blood glucose in Blantyre, Malawi [6], 3.7% diabetes
in Tanzanians [14] and 4.1% in South Africans [19]. A small
study from Tanzania found a very high diabetes prevalence
of 18% in a population of whom 12% used protease inhibi-
tors [20].
As the epidemic of non-communicable diseases in sub-
Saharan Africa gains more recognition, policy makers can
take the opportunity to integrate services for hypertension
and diabetes mellitus into the well-established HIV care
infrastructure. Appropriate diagnostic tools for both con-
ditions are inexpensive and readily available in the local
setting. Our study shows that screening of HIV patients in
care can address a large unmet need, as three-quarters of
cases of hypertension and diabetes were not diagnosed
previously. Integrated HIV-hypertension-diabetes care will
prevent patients making multiple visits to different clinics
which often generates high costs and may affect adherence
Table 2 Prevalence of hypertension, diabetes mellitus, dyslipidaemias, elevated cardio/cerebro-vascular disease risk and proteinuria
among patients at a rural and an urban HIV clinic in Zomba District, Malawi
Outcomes Overall Rural Urban p-value
n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI
Hypertension 226/952 (23.7%) 21.1–26.6 99/472 (21.0) 17.5–24.9 127/480 (26.5) 22.7–30.6 0.047
Diabetes mellitus 39/952 (4.1%) 3.0–5.6 16/472 (3.4) 2.1–5.5 23/480 (4.8) 3.2–7.1 0.275
Hypertension + diabetes mellitus 11/952 (1.2%) 0.6–2.1 3/472 (0.6) 0.2–1.9 8/480 (1.7) 0.8–3.3 0.137
Raised total cholesterol 86/554 (15.5%) 12.7–18.8 44/277 (15.9) 10.0–20.7 42/277 (15.2) 11.4–90.9 0.814
Decreased HDL cholesterol 88/554 (15.9%) 13.1–19.2 46/277 (16.6) 12.7–21.5 42/277 (15.2) 11.4–19.9 0.642
Raised total/HDL cholesterol ratio 21/554 (3.8%) 2.5–5.6 11/277 (4.0) 2.2–7.1 10/277 (3.6) 1.9–6.6 0.842
Hypertriglyceridemia 159/554 (28.7%) 25.1–32.6 87/277 (31.4) 26.2–37.1 72/277 (26.0) 21.1–31.5 0.159
Framingham score, risk >20%a 13/551 (2.4%) 1.4–4.0 8/277 (2.9) 1.4–5.7 5/274 (1.8) 0.8–4.3 0.411
WHO/ISH score, risk >20%a 13/379 (3.4%) 2.0–5.8 6/180 (3.3) 1.5–7.3 7/199 (3.5) 1.8–7.2 0.922
Proteinuriab 20/948 (2.1%) 1.4–3.2 2/472 (0.4%) 0.1–1.7 18/476 (3.8%) 2.4–6.0 0.001
n numerator, d denominator, HDL high-density lipoprotein, WHO World Health Organization, ISH International Society for Hypertension
aIndicating the risk of experiencing a fatal or non-fatal myocardial infarction or stroke in the next 10 years
bGrade 1+ and 2+ proteinuria as determined by dipstick urine testing
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[21, 22], which is crucial for the treatment of all three con-
ditions. Our observations provide insight into the extra
burden of care for HIV clinics associated with integrated
treatment for hypertension and diabetes. In Malawi, where
severe shortages of health care staff prevail even at rela-
tively advantaged HIV clinics, it will be difficult to absorb
drug treatment for all the HIV patients in care with hyper-
tension and/or diabetes, as their combined prevalence was
high (26.6%). Priority can be given to those most in need
and most likely to benefit from drug treatment. Unless
CVD, diabetes, target organ damage or high CVD risk co-
exists, a large group of HIV patients with stage I hyperten-
sion may experience limited, if any benefit from antihyper-
tensive pharmacotherapy [23, 24]. Excluding low risk
patients with mild hypertension from drug treatment
would reduce the total burden of integrated pharmaco-
therapy and it’s associated more frequent and longer clinic
visits by 50% (from 26.6 to 13.0%).
Strengths of our study include the use of robust defini-
tions of hypertension and diabetes, avoiding overestimation
of disease burden as a result of single session blood pres-
sure measurements and one-off elevated blood glucose
tests. We combined a large sample size with thorough ana-
lysis of CVD risk factors. We believe that our findings can
be extrapolated to HIV clinics in many parts of Malawi and
sub-Saharan Africa, where patients are mostly on the same
standardized ART regimens and have comparable age and
gender distributions. Because the rural and urban popula-
tions differed considerably it is useful that findings by clinic
are valid, sample sizes ensuring adequate power at each
clinic. Limitations of our study should also be considered.
Due to the cross-sectional nature of the study we were un-
able to diagnose cases that may have arisen on prospective
screening among patients with borderline results. Further,
we found that study populations were older, longer of ART
and had more female preponderance than the general clinic
populations. This could be due to the fact that during the
study period certain patients did not visit the clinic, and/or
reflect unsuccessful consecutive enrolment of attending pa-
tients. The higher age in the study population may have
biased our results towards overestimation of the prevalence
of hypertension and diabetes. The data concerning self-
reported previous stroke could not be verified with formal
medical records which may have affected accuracy. We
used FRS and WHO/IHS scores for CVD risk estimation.
Their usefulness in sub-Saharan Africans is uncertain, since
they have not been validated with clinical endpoints. Des-
pite attempts to recalibrate the FRS for HIV infection [25]
it remains equally unclear whether and to what degree HIV
infection and being on ART increase the priority to treat
hypertension compared to classic CVD risk factors. Sam-
ples for blood lipids were taken in the non-fasting state, but
differences with fasting results are generally small and im-
pact on making clinical decisions concerning CVD
prevention is believed to be very limited [26]. We did not
determine serum creatinine levels, reflecting a widespread
inability of estimating renal function in Malawian laborator-
ies, nor did we assess hypertensive retinopathy and left ven-
tricular hypertrophy and therefore we may have
underestimated the proportion of stage I hypertension pa-
tients with target organ damage.
Conclusion
Among adult Malawian HIV patients in care we found
high combined prevalence of mostly newly diagnosed
hypertension and diabetes. Integrated HIV-hypertension-
diabetes care may be individually beneficial but increases
the burden of care for busy HIV clinics. Excluding patients
with mild hypertension and low CVD risk from drug
treatment would half the overall burden of HIV patients
in need of integrated pharmacotherapy for diabetes and/
or hypertension. More research on CVD risk in HIV in-
fected Africans is urgently needed to generate evidence
that is based on clinical endpoints. The individual benefits
of integrated care for hypertension and diabetes at HIV
clinics needs further study as well as the optimal model of
care.
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